
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZFP42 (ZFP42 zinc finger protein) encodes a zinc finger protein with sequence-specific double-stranded DNA-binding activity. It is involved in regulation of female and male gonad development, suggesting a role in transcriptional control during reproductive development. The protein is reported to localize to the cytoplasm, although its precise molecular mechanisms and relationship between DNA binding and gonadal development remain incompletely characterized.
A human T-cell line originating from the peripheral blood of a 14-year-old male with childhood T-cell acute lymphoblastic leukemia, Jurkat, Clone E6-1 represents a clone of the Jurkat-FHCRC derivative. The line is classified as a T-cell lymphoblast and has been characterized with genomic and proteomic studies. It is associated with precursor T-cell acute lymphoblastic leukemia and retains the biological characteristics of its leukemia-derived origin.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 1
Reference Transcript: NM_020828
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?